{
    "nct_id": "NCT06834386",
    "official_title": "A Pilot Randomized, Open Label Trial of Orexin Receptor Antagonist for Insomnia in Hospitalized Patients With Cancer to Prevent Delirium",
    "inclusion_criteria": "* Presence of advanced active malignancy and insomnia despite nonpharmacologic management\n* Anticipated hospital course of at least 3 days post randomization as judged by the patient's primary inpatient team\n* One or more of the following risk factors of delirium:\n\n  * Age 75 or above\n  * Hearing impairment\n  * Vision impairment\n  * Initiation of 8 or new medications since start of hospitalization\n  * Chronic kidney disease III or greater\n  * Congestive heart failure\n  * Hospitalization for 14 or more days\n  * Dehydration requiring ongoing use of intravenous (IV) hydration\n  * Electrolyte imbalance requiring ongoing correction\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to consent\n* Current pregnancy\n* Women of childbearing potential (defined as women under age 55 without a personal history of surgical or chemotherapy-induced sterility)\n* Current or prior delirium in the active hospitalization\n* Concurrent use of strong/moderate CYP3A4 inducers and inhibitors (including but not limited to -azole antifungals, amiodarone, phenytoin, carbamazepine, etc.)\n* Use of any benzodiazepine, benzodiazepine receptor modulator, or first generation antihistamine class medication within 72 hours prior to enrollment\n* Personal history of narcolepsy\n* Personal history of other primary sleep disorders including obstructive sleep apnea\n* Personal history of alcohol use disorder\n* Personal history of substance use disorder\n* Personal history of cirrhosis\n* Transaminitis more than 3 times the upper limit of normal\n* History of obstructive lung disease other than asthma",
    "miscellaneous_criteria": ""
}